METHOD OF REDUCING CONTACT LENS INTOLERANCE WITH NON-DRYING ANTIHISTAMINES

Abstract

A method and preparation for reducing dry eye symptoms and promoting tear secretion in a subject in need of such treatment is disclosed. The method is useful in treating dry eye diseases. The method is also useful in reducing contact lens intolerance in the eyes. The method comprises administering to the eyes of a subject in need thereof a non-drying antihistamine compound, such as epinastine hydrochloride, in an amount effective to reduce dry eye symptoms and stimulate tear fluid secretion. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the compound include topical administration via a liquid, gel, cream, or as part of a contact lens or a continuous or selective release device; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form, injectable, intra-operative instillation or suppository form.

Description

This application is a continuation in-part of U.S. application Ser. No. 11/503,029, filed Aug. 10, 2006; which claims the benefit of U.S. Provisional Application 60/710,027, filed Aug. 19, 2005; both applications are incorporated herein by reference in its entirety.

TECHNICAL FIELD

This invention relates to a method of reducing symptoms of ocular dryness in a subject. The method is useful in relieving dry eye symptoms, increasing tear secretion, and decreasing contact lens intolerance. The method involves administering to the subject in need thereof a non-drying antihistamine compound. The present invention is illustrated by epinastine hydrochloride and bilastine.

BACKGROUND OF THE INVENTION

There are many situations where it is therapeutically desirable to increase the amount of tear fluid produced by the eye. Dry eye disease is the general term for indications produced by abnormalities of the precorneal tear film characterized by a decrease in tear production or an increase in tear film evaporation, together with the ocular surface disease and symptoms that result. Approximately 38 million Americans are affected with some type of dry eye disorder. Among the indications that are referred to by the general term “dry eye disease” are: keratoconjunctivitis sicca (KCS), age-related dry eye, Stevens-Johnson syndrome, Sjogren's syndrome, ocular cicatrical pemphigoid, blepharitis, corneal injury, infection, Riley-Day syndrome, congenital alacrima, nutritional disorders or deficiencies (including vitamins), pharmacologic side effects, contact lens intolerance, eye stress and glandular and tissue destruction, environmental exposure to smog, smoke, excessively dry air, airborne particulates, autoimmune and other immunodeficient disorders, and comatose patients rendered unable to blink.

Dry eye disease, although seen pathologically during ophthalmic exams as superficial punctate keratopathy (SPK) of the ocular surface epithelium, is largely a symptomatic disease. Chronic dryness leads to pain and irritation that is often debilitating to the subject, preventing the performance of normal daily activities such as reading, driving, etc. Dry eye is most common in postmenopausal women; however, hormone replacement therapy has not been proven to help dry eye signs and symptoms.

Currently, the pharmaceutical treatment of dry eye disease is mostly limited to administration of artificial tears (saline solution), anti-inflammatory agents (cyclosporine, steroids) and secretagogues (diquafosol, 15-HETE, rebamipide). In addition, artificial tears often have contraindications and incompatibility with soft contact lenses (M. Lemp, Cornea 9(1), S48-550 (1990)). The use of phosphodiesterase inhibitors, such as 3-isobutyl-1-methylxanthine (IBMX) to stimulate tear secretion is disclosed in U.S. Pat. No. 4,753,945. The effectiveness of these phosphodiesterase inhibitors has been investigated (J. Gilbard, et al., Arch. Ophthal, 112, 1614-16 (1994) and 109, 672-76 (1991); idem, Inv. Ophthal. Vis. Sci. 31, 1381-88 (1990)). Stimulation of tear secretion by topical application of melanocyte stimulating hormones is described in U.S. Pat. No. 4,868,154. Although these interventions can reduce inflammation and/or reduce SPK associated with dry eye, they have not been proven to significantly reduce the symptoms of dry eye.

About 34 million people wear contact lenses in the United States, with 85% of them wearing soft contact lenses. (Foulks, Am J Ophthalmol. 2006; 141:369-373) Many report contact lens intolerance such as dryness and discomfort of the eyes that limits their wear time. (Richdale, et al. Cornea 2007; 26:168-174) Contact lens wearers have decreased tear break-up time (Doughty, et al. Ophthalmic Physiol Opt. 2005; 25:119-127; Glasson, et al. Invest Ophthalmol Vis Sci. 2003; 44:5116-5124) and decreased tear volume relative to those who do not wear them (Glasson, supra). Another study echoes the decreased tear break-up time, and notes increased tear osmolality. (Nichols, et al. Invest Ophthalmol V is Sci. 2006; 47:1319-1328) Tears of contact lens-intolerant subjects are subject to degradation of tear lipids, possibly due to increased soluble phospholipase 2, compared with tolerant lens wearers. (Glasson, et al. Curr Eye Res. 2002; 25:227-235) Furthermore, contact lens wearers have less than one-half the amount of total protein in their tears relative to non-wearers, possibly due to trapping of tear film proteins on the contact lens. (Hori, et al. Cornea. 2006; 25:176-181) Those studies highlight the irritation and intolerance that can result from contact lens wear, despite advances in contact lens technology.

U.S. Pat. No. 4,313,931 discloses a method of treating reactions provoked by liberation of histamine or serotonin; bronchial asthma; allergic bronchitis; allergic rhinitis; allergic conjunctivitis; or allergic diathesis in a warm-blooded host, which comprises administering to said host an effective amount of a fused dibenzo imidazolo compound such as epinastine.

U.S. Pat. No. 5,942,503 discloses a method for treating pain such as migraine, Bing-Horton syndrome, tension headache, muscular pain, inflammatory pain or neuralgias, in a patient in need thereof which comprises administering to said patient an analgesia producing amount of epinastine or a pharmaceutically acceptable salt thereof.

U.S. Patent Publication No. 20040097486 discloses a method of treating vernal keratoconjunctivitis, giant papillary conjunctivitis, atopic keratoconjunctivitis, and allergic conjunctivitis in mammals, which comprises administering a composition comprising 0.01-0.3% of an H₁ antagonist and 0.05-1.5% of a safe steroid. Vernal keratoconjunctivitis is an allergic type of conjunctivitis, which symptoms include severe ocular itching, and mild stringy, mucous discharge. Vernal keratoconjunctivitis is different from keratoconjunctivitis sicca, which is a dry eye disease. All the above cited U.S. patents are incorporated herein by reference in their entirety.

Abelson, et al., have reported that epinastine reduces redness and itching associated with allergic conjunctivitis (M. B. Clinical Therapeutics, Vol. 26(1), 35-47, (2004)).

Ousler, et al. (Ann Allergy Asthma Immunol. 93:460-4, (2004)) reported that systemic antihistamines, such as loratadine and cetirizine hydrochloride, induced signs and symptoms associated with ocular dryness, including increased corneal and conjunctival staining, decreased TFBUT, and increased ocular discomfort in healthy individuals.

Dry eye disease is different from allergic conjunctivitis; the two diseases have different patient populations. Dry eye symptoms are dryness, photophobia, foreign body sensation and grittiness in the eyes. Dry eye symptoms are different from the main complaint of itching associated with allergy, and are not related to histamine activity or allergic response. Redness of the eyes is not a main sign of dry eye disease. The primary end points for studying allergic conjunctivitis are generally ocular itching and conjunctival hyperemia. The primary end points for studying dry eye diseases are corneal staining, tear volume (Schirmer tests), dryness, photophobia, foreign body sensation and grittiness.

As a result of the ineffectiveness and inconvenience of current therapies of dry eyes, there remains a need to provide a method for the treatment of dry eye symptoms, which is not only effective, but also free of significant side effects.

SUMMARY OF THE INVENTION

The present invention is directed to a method of reducing dry eye symptoms and stimulating tear secretion in a subject in need of such treatment. The method of the present invention can be used to reduce dry eye symptoms and increase tear production for any reason, including, but not limited to, treatment of dry eye disease. The method of the present invention can also be used for reducing contact lens intolerance. The method comprises the step of administering to the eyes of a subject in need thereof an effective amount of a non-drying antihistamine compound. A preferred method comprises topically administering a liquid, a gel, or a semi-solid preparation of a non-drying antihistamine, such as epinastine hydrochloride or bilastine, in an amount effective to reduce dry eye symptoms and to stimulate tear secretion.

The present invention is useful as a wash or irrigation solution to eyes of those who are unable to blink, for example, patients who cannot blink due to muscle or nerve damage, neuromuscular blockade or loss of the eyelids, comatose patients, or conscious individuals during surgery.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a method of reducing dry eye symptoms such as dryness, photophobia, foreign body sensation and grittiness in a dry eye subject. The present invention is also directed to a method of stimulating tear secretion in a subject suffering from dry eye symptoms. The method comprises the step of first identifying a subject suffering from dry eye symptoms, then administering to the eyes of such subject an effective amount of a non-drying antihistamine compound.

Dry eye symptoms can be due to keratoconjunctivitis sicca (KCS), age-related dry eye, contact lens intolerance, Stevens-Johnson syndrome, Sjogren's syndrome, ocular cicatrical pemphigoid, blepharitis, corneal injury, infection, Riley-Day syndrome and congenital alacrima. Dry eye symptoms can also be caused by nutritional (such as vitamin) disorders or deficiencies, pharmacologic side effects, eye stress and glandular and tissue destruction, environmental exposure to smog, smoke, excessively dry air, airborne particulates, autoimmune and other immunodeficient disorders.

The present invention is useful in reducing contact lens intolerance, for example, due to dryness in the eyes. The methods reduces ocular symptoms associated with contact lens wearing in a subject who develops contact lens intolerance due to dryness in the eyes. The method comprises identifying a subject suffering from contact lens intolerance, and then administering to the eyes of said subject an effective amount of a non-drying antihistamine such as epinastine or bilastine. The method of the present invention can increase the total contact lens wearing time per day in a subject, or increase comfortable contact lens wearing time per day in a subject, or make wearing contact lens more comfortable to the user. In one embodiment, the subject suffers from allergic conjunctivitis. Seasonal allergic conjunctivitis often exacerbates the symptoms of contact lens intolerance, and the present invention is effective in reducing such symptoms.

Applicants have discovered that non-drying antihistamines promote tear secretion and reduce symptoms of dry eye via H₁ receptor blockade on corneal nerves in the absence of an allergic response. The method of the present invention is an improvement upon the current most commonly used treatment of dry eye disease—artificial tears (i.e., saline solution), anti-inflammatory agents (cyclosporine), and secretagogues (15-HETE, and rebamipide). The method of the present invention stimulates a patient's own tear production and secretion, while providing analgesia of the symptomatic corneal irritation that occurs in dry eye. The method of the present invention has the benefit of acting as a topical analgesic in irritated eyes such as chronic dry eye and chronic contact lens wear with the added benefit of increased tear secretion.

The present invention is useful as a wash or irrigation solution to eyes of those who are unable to blink, for example, patients who cannot blink due to muscle or nerve damage, neuromuscular blockade or loss of the eyelids, comatose patients, or conscious individuals during surgery.

The term “non-drying antihistamine compounds,” as used herein, are antihistamines and the pharmaceutically acceptable salts thereof that block H₁ receptors and do not have drying effects on the eyes as indicated by measuring tear volume. Non-drying antihistamine compounds generally do not have significant binding affinity for muscarinic receptors (e.g. M₁, M₂ and M₃) or do not have significant anticholinergic activities. Non-drying antihistamine compounds include epinastine, bilastine, fexofenadine, cetirizine, emedastine, levocabastine, mequitazine, chlorpheniramine, brompheniramine, astemizole, terfenadine, rocastine, 5-[2-[4-bis(4-fluorophenyl)hydroxymethyl-1-piperid-inyl]ethyl]-3-methyl]-2-oxazolidinone ethanedioate, pyrilamine, clemastine, azelastine, ketotifen, and mapinastine. Preferred non-drying antihistamine compounds of this invention are epinastine, bilastine, cetirizine, and fexofenadine; with epinastine and bilastine being further preferred.

Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects. Pharmaceutically acceptable salts include any addition salt with a pharmacologically acceptable acid as well as the free base. Examples of pharmaceutically acceptable salts are hydrochloride, hydrobromide, fumarate, acetate, etc.

Epinastine is the generic name of 3-amino-9,13b-dihydro-1H-dibenz[c,f]-imidazo[5,1-a]azepine. Epinastine hydrochloride was described by Fugner et al. (Arzneimittelforschung 38 (1988): 1446-1453). The active compound can be used in the form of a racemate or in the form of pure enantiomers or as a mixture of different proportions of both enantiomers. A common therapeutic salt for epinastine is hydrochloride. The invention described herein, however, is not limited to the hydrochloride but relates to any addition salt with a pharmacologically acceptable acid as well as the free base.

Bilastine is the generic name of 2-[4-(2-(4-(1-(2-ethoxyethyl)benzimidazole-2-yl)piperidine-1-yl)ethyl)phenyl)phenyl]-2-methyl propanoic acid. Bilastine was described in U.S. Pat. No. 5,877,187. The active compound can be used in the form of a racemate or in the form of pure enantiomers or as a mixture of different proportions of both enantiomers. The invention described herein, however, is not limited to the compound but relates to any addition salt with a pharmacologically acceptable acid or base.

The present invention is concerned primarily with the treatment of human subjects, but can also be employed for the treatment of other mammalian subjects, such as dogs and cats, for veterinary purposes.

A preferred method of the present invention comprises topically administering a liquid or gel suspension of a non-drying antihistamine, such as epinastine hydrochloride, to the ocular surface of a subject, in an amount effective to reduce dry eye symptoms and to stimulate tear secretion.

The active compounds disclosed herein can be administered to the eyes of a patient by any suitable means, but are preferably administered as a liquid, a gel, or a semi-solid preparation of the active compound in the form of drops, spray or gel. Alternatively, the active compounds can be applied to the eye via liposomes. Further, the active compounds can be infused into the tear film via a pump-catheter system. Another embodiment of the present invention involves the active compound contained within a continuous or selective-release device, for example, membranes such as, but not limited to, those employed in the OCUSERT™ System (Alza Corp., Palo Alto, Calif.), a polymeric ocular inserts for the administration of drugs. As an additional embodiment, the active compounds can be contained within, carried by, or attached to contact lenses or other compatible controlled release materials, which are placed on the eye. Another embodiment of the present invention involves the active compound contained within a swab or sponge which can be applied to the ocular surface. Another embodiment of the present invention involves the active compound contained within a liquid spray which can be applied to the ocular surface. Another embodiment of the present invention involves an injection of the active compound directly into the lacrimal tissues or onto the eye surface.

The concentration of the active compound included in the topical solution is an amount sufficient to reduce dry eye symptoms and stimulate tear secretion. This solution is preferably an aqueous solution of a non-drying antihistamine compound and is in the range of 0.005-1.0%, preferably 0.01% to 0.2%, preferably 0.01% to 0.1%, and more preferably about 0.05% (w/v) or about 0.1% (w/v). The preferred formulation includes a preservative, such as benzalkonium chloride (0.01% w/v) and inactive ingredients: edetate sodium, purified water, sodium chloride, sodium phosphate monobasic, sodium hydroxide and/or hydrochloric acid to adjust the pH to about 6-8, preferably about 7.

Depending upon the solubility of the particular formulation of active compound administered, the daily dose to reduce symptoms and promote tear secretion can be divided among one or several unit dose administrations. The total daily dose for epinastine, for example, can range from one drop (about 50 μl), one to four times a day, depending upon the age and condition of the subject. A currently preferred regimen for epinastine is one drop of 0.05% (w/v) solution, about 1 to 2 times a day.

The topical solution containing the active compound can also contain a physiologically compatible vehicle, as those skilled in the ophthalmic art can select using conventional criteria. The vehicles can be selected from the known ophthalmic vehicles which include, but are not limited to, saline solution, water polyethers such as polyethylene glycol, polyvinyls such as polyvinyl alcohol and povidone, cellulose derivatives such as methylcellulose and hydroxypropyl methylcellulose, petroleum derivatives such as mineral oil and white petrolatum, animal fats such as lanolin, polymers of acrylic acid such as carboxypolymethylene gel, vegetable fats such as peanut oil and polysaccharides such as dextrans, and glycosaminoglycans such as sodium hyaluronate and salts such as sodium chloride and potassium chloride.

In addition to the topical method of administration described above, there are various methods of administering the active compounds of the present invention systemically. One such method involves an aerosol suspension of respirable particles comprised of the active compound, which the subject inhales. The active compound is absorbed into the bloodstream via the lungs or contact the lacrimal tissues via nasolacrimal ducts, and subsequently contact the lacrimal glands in a pharmaceutically effective amount. The respirable particles can be liquid or solid, with a particle size sufficiently small to pass through the mouth and larynx upon inhalation; in general, particles ranging from about 1 to 10 microns, but more preferably 1-5 microns, in size are considered respirable.

Liquid pharmaceutical compositions of the active compound for producing a nasal spray or nasal or eye drops can be prepared by combining the active compound with a suitable vehicle, such as sterile pyrogen free water or sterile saline by techniques known to those skilled in the art.

Other method of systemic administration of the active compound involves oral administration, in which pharmaceutical compositions containing non-drying antihistamines, such as epinastine, are in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients can be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets can be uncoated or they can be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

A preferred systemic dosage form is oral administration. In a tablet, the preferred dose is 1-50 mg, preferably 5-25 mg and most preferably 10-20 mg of epinastine once or twice a day. Alternately, an oral syrup or dry syrup such as 1-2 teaspoons of a 1% (w/v) suspension once or twice a day can be administered.

Additional method of systemic administration of the active compound to the eyes of the subject involves a suppository form of the active compound, such that a therapeutically effective amount of the compound reaches the eyes via systemic absorption and circulation.

Further method of administration of the active compound involves direct intra-operative instillation of a gel, cream, powder, foam, crystal, liposomes, emulsions, spray or liquid suspension form of said compound, such that a therapeutically effective amount of the compound reaches the eyes via systemic absorption and circulation.

The invention is illustrated further by the following examples which are not to be construed as limiting the invention in scope or spirit to the specific procedures described in it. An example in accordance with the invention was conducted on animals with dry eyes. It is recognized by those skilled in the art that results of ophthalmologic tests carried out in the aforementioned dry eye animal disease models have close correlation with humans afflicted with dry eye disease, and, therefore, the results provide an accurate prediction of therapeutic efficacy in humans.

EXAMPLES

Example 1

Effect of Topical Epinastine and Olopatadine on Tear Volume in Mice

Purpose

An in vivo example in accordance with the invention was conducted on an animal (mouse) model. The following example investigated the effects of topical epinastine and olopatadine ophthalmic solutions on tear volume in C57BL6 mice.

Methods

A total of 80 C57BL6 mice were divided into 3 treatment groups: epinastine (ELESTAT®, Inspire, Durham, N.C.), olopatadine (PATANOL®, Alcon, Ft. Worth, Tex.) and untreated controls. An additional group of 5 mice were treated with topical atropine 1% as an anticholinergic control. Mice in the epinastine, olopatadine and atropine groups had 1 μL of their respective drug instilled two times a day on the ocular surface. After two and four days of treatment, tear volume measurements were made with a phenol red impregnated cotton thread (Zone-Quick, Menicon, San Mateo, Calif.) 15, 45, 90, 120 and 240 min after the last instillation of the drug. A baseline tear measurement was performed before initiation of drug therapy. The untreated group had tear volume measurements done at the same time points. The length of tear wetting on the cotton thread was measured with a Nikon SMZ1500 microscope using MetaVue© software. A standard curve of cotton thread uptake was made using a glass micropipette with a known volume of a basic solution. Mouse tear volumes were calculated using regression analysis calculated by Microsoft® Excel. ANOVA with Tukey's Multiple Comparison Test was used for statistical analysis using GraphPad Prism® software.

Results

After 2 days of treatment, the epinastine-treated group showed higher mean tear volumes at 15, 45, 90 and 240 minutes than the olopatadine-treated group, reaching a statistically significant difference in tear volume at 45 min (P<0.001). The untreated group also had a statistically higher tear volume than the olopatadine group at 15 min (P<0.05) and 45 min (P<0.05). The epinastine-treated group showed an increased production of tears over the untreated group, but the difference was not statistically significant.

Similar results were found in tear volumes measured after 4 days of treatment; volumes were higher at all time points measured in the epinastine group, reaching a statistical significance over olopatadine at 45 min (p<0.05). The atropine-treated group showed no detectable tear volume at 15 min, 45 min and 90 min, but there was a return to baseline levels at 240 min.

Conclusions

The results indicate that olopatadine caused a significant decrease in tear volume, which could be due to the anticholinergic effects. Topical epinastine was not found to inhibit tear secretion, but rather increased tear production.

Example 2

Evaluation of the Ocular Drying Effect of Two Antihistamines: Topical Epinastine and Systemic Loratadine

Purpose

An in vivo example in accordance with the invention was conducted in human subjects. The following example investigated the effects of topical treatment with ELESTAT® (epinastine HCl ophthalmic solution, 0.05% w/v) and systemic treatment with loratadine, 10 mg, on parameters of ocular surface health, including tear production, tear flow and ocular surface staining.

Methods

Eighteen individuals completed a single-center, open label, four-visit, crossover study.

Visit 1 (Day 0): Baseline

Informed Consent was obtained; demographic data, medical history, and medication history were captured for consenting individuals. Baseline ophthalmic safety examinations were performed, including visual acuity and slit lamp biomicroscopy. Fluorophotometry measurements were taken initially at time 0, then at time 1, 4, 7, 10, 13, 16, 19 minutes. The time 0 measurement was taken as a background fluorescence measurement. After background assessment, 1 μl of 2% unpreserved sodium fluorescein was instilled into the right eye of every subject throughout the study. Tear film break-up measurements and corneal and conjunctival staining were performed to further quantify ocular dryness. Tear film break-up time is a test of tear function. It is the time to the development of a dry spot on the cornea (i.e. break up of the pre-corneal tear film). Corneal and conjunctival staining are ways to measure ocular surface damage due to drying.

For the tear film break-up time (TFBUT) evaluations, 5 μl of 2% unpreserved sodium fluorescein was instilled into each eye. Corneal and conjunctival staining evaluations were performed using 5 μl of 2% unpreserved sodium fluorescein, instilled into each eye. The examiner waited one minute after instillation then began the evaluation and graded the three corneal regions and the two conjunctival regions. Corneal and conjunctival staining evaluations were also performed using 10 μl of 1% unpreserved lissamine green, instilled into each eye. The examiner graded the cornea (inferior, superior, and central) and conjunctiva (nasal and temporal) using a standardized scale from 0 to 4 points. Participants were then randomized to receive either oral loratadine 10 mg daily or ocular epinastine (ELESTAT®) 1 drop twice daily for the following 4 days.

Visit 2 (Day 4)

Medical and medication histories were updated, participants were queried about adverse events, and treatment compliance was evaluated. Tear volume and tear flow were evaluated via fluorophotometry. Ophthalmic examinations, including visual acuity, slit lamp biomicroscopy, TFBUT measurement, and corneal and conjunctival staining evaluations (using fluorescein and lissamine) were conducted. Subjects were instructed to refrain from the use of any other antihistamines and ophthalmic medications for 10 consecutive days.

There was no treatment after visit 2. This was a washout period to allow for the complete elimination of loratadine from systemic circulation.

Visit 3 (Day 14): Crossover

Medical and medication histories were updated, participants were queried about adverse events, and treatment compliance was evaluated. Tear volume, tear flow ophthalmic examinations (including visual acuity, slit lamp biomicroscopy, TFBUT measurement, and corneal and conjunctival staining evaluations) were conducted as before. Participants received the opposite medication from visit 1, followed by 4 days of treatment. Patients who received epinastine at visit 1 received loratadine and patients who received loratadine at visit 1 received epinastine.

Visit 4 (Day 18)

Medical and medication histories were updated, participants were queried about adverse events, and treatment compliance was evaluated. Tear volume, tear flow ophthalmic examinations were conducted as before.

Results

After 4 days of treatment, tear volume increased 7% in ELESTAT®-treated subjects compared to a 34% decrease in loratadine-treated subjects (p=0.0357). The ELESTAT® group also had a 10% increase in tear flow compared to a 35% decrease in the loratadine group (p=0.0378).

Similar results were seen with corneal and conjunctival staining. In ELESTAT®-treated participants, corneal and conjunctival staining decreased by 1%. Whereas in loratadine-treated participants, corneal and conjunctival staining increased by 22% (p=0.0478), which indicates an increase in ocular surface damage due to drying in loratadine-treated participants.

Although no significant change in TFBUT was observed after 4 days of treatment with loratadine, a trend was evident. Mean TFBUT decreased by 22% (p=0.142). In ELESTAT®-treated subjects, TFBUT decreased by less than 1%. The results again demonstrated that treatment with loratadine caused drying of the ocular surface whereas epinastine did not.

Conclusions

The above results indicate that epinastine increased both tear volume and tear flow after 4 days of treatment, while loratadine caused statistically significant decreases in both tear volume and tear flow. Additionally, ELESTAT® reduced corneal and conjunctival staining, while loratadine induced a statistically significant increase in staining. ELESTAT® also had no effect on tear film break-up time, while loratadine decreased TFBUT.

Example 3

Effect of Topical Epinastine on Contact Lens-Wearing Subjects

Purpose

This study was undertaken to assess the response of contact lens-wearing subjects, who had a history of allergic conjunctivitis, to epinastine or a control solution (rewetting drops).

Methods

This was a multi-center, open-label, randomized study that compared (a) epinastine 0.05% ophthalmic solution (ELESTAT®, Inspire Pharmaceuticals, Inc., Durham, N.C.) plus rewetting drops (Walgreens Rewetting Drops, Walgreens, Deerfield Ill.) with (b) rewetting drops alone. The subjects wore contact lenses, but were contact lens intolerant. The study started during the spring allergy season because seasonal allergic conjunctivitis may exacerbate the symptoms of contact lens intolerance.

146 subjects had 3 clinic visits over a 2-week period. The first was the screening visit to determine eligibility. Following that, subjects completed a daily diary card to assess compliance and capture baseline values during a 5-7 day run-in period with rewetting drops. At the next visit, each subject was dispensed a new pair of contact lenses and randomly assigned to receive either (a) epinastine 0.05% ophthalmic solution BID (twice a day) plus rewetting drops (75 subjects), or (b) rewetting drops only as needed, but at least twice a day (71 subjects), for a 5-7 day treatment period. During the treatment period, subjects recorded the length of time that contact lens wear was comfortable, the total time of wear, ocular itch, overall ocular comfort, and use of rewetting drops. Subjects receiving epinastine were instructed to remove contact lenses prior to instillation, allow at least 10 minutes before reinsertion, and allow 15 minutes before administering rewetting drops. Each instillation was to occur 8-12 hours after the previous one, with the evening application coming after removal of lenses for the day. The final visit came after the 5-7 day treatment period and allowed collection of the data and unused study medication.

Ocular comfort was scored on a scale of 0-4, with 0=very comfortable, 1=somewhat comfortable, 2=mildly uncomfortable, 3=moderately uncomfortable, and 4=very uncomfortable.

Ocular itch was scored on a scale of 0-4, with 0=none, 1=mild, 2=moderate, 3=severe, and 4=extremely severe.

Baseline values presented are the average of all entries recorded during the run-in phase of the study. P values are based on an ANCOVA model that included the treatment, the site, and the baseline value. Values for Day 1 are not included in the analysis for contact lens wear time, ocular itching, ocular comfort, and rewetting drop usage because they were a mixture of run-in and treatment period values.

Results

Table 1 summarizes the efficacy results, which show the mean change from baseline including comfortable contact lens wearing time, total contact lens wear, ocular itch, overall eye comfort, and frequency of rewetting drop use.

During the treatment period from Day 2 through Day 7, the epinastine group had greater increases from baseline in comfortable wearing time compared with the control group receiving rewetting drops alone. The average increase in comfortable wearing time over the entire treatment period was significantly greater for the epinastine group, 1.33 hours (from 7.88 hours of comfortable wear time at baseline to 9.21 hours, averaged over the treatment period) versus 0.43 hours (from 6.96 hours at baseline to 7.39 hours averaged over the treatment period) for the rewetting drops group (P=0.012).

The mean increase from baseline in total contact lens wearing time over the treatment period was also significantly greater for the epinastine group, 0.35 hours versus −0.32 hours for the rewetting drops group (P=0.008). The average total wearing time over the treatment period was 13.22 hours for the epinastine group versus 12.26 hours for the rewetting drops group.

On all treatment days, epinastine provided significantly greater mean reduction from baseline in ocular itching compared with rewetting drops alone, with P=0.005, P=0.007, P=0.015, P<0.001, P=0.001, and P=0.001 for Days 2 through 7, respectively, and P<0.001 for the mean of all treatment days. Average ocular itch scores over the entire treatment period were 1.11 for epinastine and 1.59 for rewetting drops alone. Change from baseline in mean ocular itch score was −0.54 for epinastine and −0.07 for rewetting drops alone.

Both groups displayed comparable overall eye comfort at baseline, during the run-in period. On all treatment days, epinastine provided a significantly greater improvement from baseline in overall eye comfort compared with the control treatment. Over the entire treatment period, mean overall eye comfort was 1.43 in the epinastine group versus 1.87 in the rewetting drops only group. Change from baseline in mean overall eye comfort was −0.48 for epinastine and −0.07 for rewetting drops alone.

Epinastine provided significantly greater reduction from baseline in use of rewetting drops compared with the control group. The average use of rewetting drops over the entire treatment period was 2.79 uses per day for the epinastine group and 3.35 uses per day for the control group. Change from baseline in mean frequency of rewetting drop use was −0.55 for epinastine and −0.06 for rewetting drops alone.

TABLE 1
Mean change from baseline
		Rewetting
Average during	ELESTAT ®	Drops
Treatment Period	(n = 75)	(n = 71)	P-value
Comfortable contact	1.331	0.433	0.012
lens wear
Total contact	0.346	−0.320	0.008
lens wear
Ocular itch	−0.54	−0.07	<0.001
Overall eye comfort	−0.48	−0.07	0.001
Frequency of	−0.55	−0.06	0.012
rewetting drop use

Example 4

M3 Receptor Potency and H1 Receptor Potency of Antihistamines

Materials

Histamine, acetylcholine, carbachol, ketotifen and fexofenadine were obtained from Sigma (St. Louis, Mo.). Cetirizine was obtained from Ryan Scientific (Mount Pleasant, S.C.), while desloratadine was obtained from LKT Laboratories (St. Paul, Minn.). Epinastine, olopatadine and azelastine were manufactured (with a minimal purity of 99%) for Inspire by custom synthesis using contract vendors. Bilastine was prepared by FAES FARMA (Spain).

Cell Lines

C6 rat glioma and CHO-K1 (Chinese hamster ovary) cells were obtained from the American Type Culture Collection (ATCC, Manassas, Va.). To establish a recombinant cell line expressing the human histamine H1 receptor, CHO-K1 cells were transfected with the plasmid pcDNA3.1(+) (Invitrogen, Carlsbad, Calif.) containing the DNA sequence encoding the human histamine H1 receptor. Recombinant cell lines stably expressing independently each of the five human muscarinic receptors (M1, M2, M3, M4 or M5) were established by transfecting C6 rat glioma cells with the plasmid pcDNA3.1(+) containing the DNA sequence encoding the muscarinic receptor subtypes. Moreover, two of the muscarinic receptor subtypes (M2 and M4) that signal through the Gαi protein were expressed in C6 cells that also expressed a functional chimeric Gq/i protein allowing these receptors to signal via calcium mobilization.

Methods and Results

CHO-K1 H₁ cells were exposed to different concentrations of 8 different marketed antihistamines such as ketotifen (ZADITOR®), epinastine (ELESTAT®), desloratadine (CLARINEX®), olopatadine (PATANOL®), bilastine, cetirizine (ZYRTEC®), fexofenadine (ALLEGRA®), and azelastine (OPTIVAR®), for 45 minutes followed by the stimulation of 6 μM histamine. Dose response curves were generated. IC₅₀ values of the 8 antihistamines were calculated from the dose response curves, which are presented in Table 2 below. The results of these experiments are presented in order of potency with the most potent antihistamine (ketotifen) on the left side of the table and the least potent (azelastine) on the right side.

TABLE 2
IC50 Values for Antihistamines at the H1 Receptor (Reported in [nM] + SEM)
Ketotifen	Epinastine	Desloratadine	Olopatadine	Bilastine	Cetirizine	Fexofenadine	Azelastine
3 ± 0.3	19 ± 3	29 ± 1	101 ± 8	165 ± 44	557 ± 551	1,767 ± 112	1,960 ± 500

C6 cell lines expressing a functional recombinant M₁-M₅ receptor, or 1321N1 astrocytoma cells expressing the endogenous M₃ receptor were incubated with the indicated concentrations of antihistamines for 2.5 or 45 minutes, followed by stimulation with an EC₉₀ concentration (500 nM) of acetylcholine. Antihistamines with anticholinergic properties (desloratadine, ketotifen, azelastine and olopatadine) inhibited muscarinic receptor signaling in a dose-dependent manner and allowed the calculation of IC₅₀ values that are shown below in Table 3. Due to lack of anticholicholinegic properties, the IC₅₀ values of epinastine, bilastine, cetirizine, and fexofenadine could not be calculated.

TABLE 3
IC50 of Antihistamines at Muscarinic Receptors (Reported in [nM])
	Ketotifen	Desloratadine	Olopatadine	Azelastine
M1	217 ±	65 ±	1,742 ±	577 ±
	14	6	353	80
M2	209 ±	21 ±	7,665 ±	2,415 ±
	32	2	811	604
M3	1,432 ±	165 ±	7,976 ±	16,760 ±
	6	14	767	484
M3	1,227 ±	80 ±	41,900 ±	10,190 ±
(1321N1)	90	9	2,625	887
M4	561 ±	218 ±	13,070 ±	8,111 ±
	85	30	1,411	982
M5	138 ±	116 ±	10,700 ±	3,258 ±
	27	7	1,356	457

Conclusions:

The Results demonstrate that epinastine and bilastine have high antihistamine potency and very low antimuscarinic effects.

Furthermore, the results demonstrate that ketotifen, azelastine, desloratadine and olopatadine are relatively potent antihistamines, but also display potentially undesirable anticholinergic activity. Fexofenadine and cetirizine have the desired weak anticholinergic activity but are also weak antihistamines.

Example 5

Effect of Topical Bilastine on Tear Volume in Mice

Purpose

The following example investigates the effects of topical bilastine ophthalmic solutions on tear volume in C57BL6 mice.

Methods

C57BL6 mice are divided into 2 groups: 0.1% (w/v) bilastine-treated and untreated controls. An additional small group of mice is treated with topical atropine 1% as an anticholinergic control. Mice in the bilastine and atropine groups have 1 μL of their respective drug instilled two times a day on the ocular surface. After two and four days of treatment, tear volume measurements are made with a phenol red impregnated cotton thread (Zone-Quick, Menicon, San Mateo, Calif.) at time points such as 15, 45, 90, 120 and 240 min after the last instillation of the drug. A baseline tear measurement is performed before initiation of drug therapy. The untreated group has tear volume measurements done at the same time points. The length of tear wetting on the cotton thread is measured with a Nikon SMZ1500 microscope using MetaVue© software. A standard curve of cotton thread uptake is made using a glass micropipette with a known volume of a basic solution. Mouse tear volumes are calculated using regression analysis calculated by Microsoft® Excel. ANOVA with Tukey's Multiple Comparison Test was used for statistical analysis using GraphPad Prism® software.

The tear volumes of bilastine-treated group, the atropine-treated group, and the control untreated group at different time points are compared.

Example 6

Effect of Topical Bilastine on Ocular Drying Effects in Human Subjects

Purpose

The following example investigates the effects of topical treatment with bilastine, on parameters of ocular surface health, including tear production, tear flow and ocular surface staining.

Methods

Visit 1 (Day 0): Baseline

Baseline ophthalmic safety examinations are performed, including visual acuity and slit lamp biomicroscopy. Fluorophotometry measurements are taken initially at time 0, then at time 1, 4, 7, 10, 13, 16, 19 minutes. The time 0 measurement is taken as a background fluorescence measurement. After background assessment, 1 μl of 2% unpreserved sodium fluorescein is instilled into the right eye of every subject throughout the study as needed. Tear film break-up measurements and corneal and conjunctival staining are performed to further quantify ocular dryness. Tear film break-up time is a test of tear function. It is the time to the development of a dry spot on the cornea (i.e. break up of the pre-corneal tear film). Corneal and conjunctival staining are ways to measure ocular surface damage due to drying.

For the tear film break-up time (TFBUT) evaluations, 5 μl of 2% unpreserved sodium fluorescein is instilled into each eye. Corneal and conjunctival staining evaluations are performed using 5 μl of 2% unpreserved sodium fluorescein, instilled into each eye. The examiner waits one minute after instillation then begins the evaluation and grades the three corneal regions and the two conjunctival regions. Corneal and conjunctival staining evaluations are performed using 10 μl of 1% unpreserved lissamine green, instilled into each eye. The examiner grades the cornea (inferior, superior, and central) and conjunctiva (nasal and temporal) using a standardized scale from 0 to 4 points. Participants then receive bilastine (0.1% w/v) 1 drop twice daily for the following 4 days.

Visit 2 (Day 4)

Tear volume and tear flow are evaluated via fluorophotometry. Ophthalmic examinations, including visual acuity, slit lamp biomicroscopy, TFBUT measurement, and corneal and conjunctival staining evaluations (using fluorescein and lissamine) are conducted after 4 days of treatment.

The results of tear volume, TFBUT, corneal staining, and conjunctival staining after 4-day treatment are compared with the baseline values.

The invention, and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the present invention and that modifications may be made therein without departing from the scope of the present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

Claims

1. A method of reducing contact lens intolerance, comprising the steps:

identifying a subject suffering from contact lens intolerance, and

administering to the eyes of said subject an effective amount of a compound 3-amino-9,13b-dihydro-1H-dibenz(c,f) imidazo (1,5-a)azepine, or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1, wherein said pharmaceutically acceptable salt is hydrochloride.

3. The method according to claim 1, wherein said contact lens intolerance is due to dryness in the eyes.

4. The method according to claim 1, wherein said method increases tear production.

5. The method according to claim 1, wherein said method increases total contact lens wearing time per day in the subject.

6. The method according to claim 1, wherein said method increases comfortable contact lens wearing time per day in the subject.

7. The method according to claim 1, wherein said administration is topical administration of said compound to the ocular surface of the eyes.

8. The method according to claim 7, wherein said compound is administered in a topical solution at a concentration of 0.01-0.2% (w/v).

9. The method according to claim 8, wherein said concentration is 0.01-0.1% (w/v).

10. The method according to claim 9, wherein said concentration is about 0.05% (w/v).

11. The method according to claim 7, wherein said topical administration is administration of said compound via a carrier vehicle selected from the group consisting of drops of liquid, liquid wash, gels, ointments, sprays, liposomes, emulsions and suspensions.

12. The method according to claim 1, wherein said contact lens is soft contact lens.

13. The method according to claim 1, wherein said subject suffers allergic conjunctivitis.

14. The method according to claim 13, wherein said allergic conjunctivitis is seasonal allergic conjunctivitis.